New drug development for pediatric oncology Steven WeitmanLisa CarlsonCharles B. Pratt OriginalPaper Pages: 1 - 10
Pediatric drug development: a perspective from the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) Malcolm SmithPeter T. C. Ho OriginalPaper Pages: 11 - 22
Phase I trials in paediatric oncology — the European perspective E. J. EstlinS. AblettA. D. J. Pearson OriginalPaper Pages: 23 - 32
The importance of Phase I/II trials in pediatric oncology Craig A. MacArthurTeresa Vietti OriginalPaper Pages: 33 - 35
Topoisomerase I interactive drugs in children with cancer Clinton F. StewartWilliam C. ZamboniCharles B. Pratt OriginalPaper Pages: 37 - 47
New microtubular agents in pediatric oncology Nita L. SeibelGregory H. Reaman OriginalPaper Pages: 49 - 54
Pharmacologic strategies for the treatment of meningeal malignancy Susan M. BlaneyDavid G. Poplack OriginalPaper Pages: 69 - 85
Folate, antifolates, and folate analogs in Pediatric Oncology Martina C. HumBarton A. Kamen OriginalPaper Pages: 101 - 111